NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Bausch Health Companies Inc. BHC
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$10.3B
▲ 6.7% vs FY2024
EPS · FY25
$0.42
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
1.5%
Dividend coverage
-0.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 10.3B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
USD 0.42
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
—
Return on equity, FY2025
ROE
Operating margin17.7%
Net margin1.5%
Return on assets0.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+8.1%
+5.0%
−0.2%
+15.5%
Net income
−5.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.37B
Shares outstanding, FY2025
Change, 5 years+4.3%
Change, 10 years+8.0%
The share count grew 4% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 26.4B
total assets, end of FY2025
Total assetsUSD 26.4B
EquityUSD -554.0M
CashUSD 1.3B
Gross debtUSD 20.8B
Net debtUSD 19.5B
Current ratio1.47×
Net debt stands at -3521% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
10.3
9.6
8.8
8.1
8.4
8.0
8.6
8.4
8.7
9.7
10.4
8.2
5.8
3.5
2.4
1.2
0.8
0.8
Operating income $B
1.8
1.5
1.0
0.5
0.5
0.7
−0.2
−2.4
0.1
−0.6
1.5
2.0
−0.4
0.1
0.3
−0.1
0.2
0.1
EBITDA $B
2.0
1.7
1.1
0.6
0.6
0.9
−0.0
−2.2
0.3
−0.4
1.7
2.2
−0.3
0.1
0.3
−0.1
0.2
·
Income tax $B
0.2
0.2
0.2
0.1
−0.1
−0.4
−0.1
−0.0
−4.1
−0.0
0.1
0.2
−0.5
−0.3
−0.2
−0.0
−0.0
−0.1
Net income $B
0.2
−0.0
−0.6
−0.2
−0.9
−0.6
−1.8
−4.1
2.4
−2.4
−0.3
0.9
−0.9
−0.1
0.2
0.4
0.4
0.2
EPS, diluted $
0.42
−0.13
−1.62
−0.62
−2.64
−1.58
−5.08
−11.81
6.83
−6.94
−0.85
2.58
−2.70
−0.38
0.49
−1.06
1.11
1.25
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
1.28
0.65
1.50
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
97
36
90
ROE %
·
·
·
·
−442.0
−70.1
−94.2
−96.6
53.4
−53.1
−5.1
16.9
−19.5
−3.0
3.6
11.7
30.0
·
Shares out B
0.37
0.37
0.37
0.36
0.36
0.36
0.35
0.35
0.35
0.35
0.34
0.33
0.33
0.30
0.31
0.30
0.16
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed